Immune Checkpoint Inhibitor–Associated Cardiovascular Toxicity: Mechanisms, Clinical Manifestations, and Clinical Impact
Cardiovascular Toxicology · 2026
DOI: 10.1007/s12012-026-10131-w ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Cardiovascular Toxicology, 2026. Verfasst von Zhengyu Chen und 4 weiteren Autor:innen. Beteiligte Einrichtung: School of Heilongjiang, University of Chinese Medicine, Harbin, China. Hauptthemen laut MEDLINE: Immune Checkpoint Inhibitors, Cardiovascular Diseases, Neoplasms, Antineoplastic Agents, Immunological. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 114 Literaturangaben. Gefördert von: 2024 Annual Hospital-Level Talent Special Fund of the Fourth Affiliated Hospital of Heilongjiang University of Chinese Medicine, Heilongjiang Province "Outstanding Young Teachers Basic Research Support Program" Project, Scientific Research Project of Heilongjiang University of Chinese Medicine.
Abstract (Originalsprache)
Immune checkpoint inhibitors (ICIs) represent a class of novel anticancer agents that enhance T cell-mediated recognition and elimination of tumor cells by inhibiting immune checkpoints such as CTLA-4 and PD-1/PD-L1. These therapeutics are widely employed in the treatment of various malignancies, including melanoma and non-small cell lung cancer, and have markedly improved clinical outcomes. However, ICIs are associated with immune-related adverse events (irAEs). Among these, cardiovascular toxicities, though relatively uncommon (occurring in approximately 3.1% of patients receiving monotherapy and 5.8% on combination therapy), are linked with the highest mortality rates. Cardiovascular toxicities associated with ICIs mainly encompass myocarditis (incidence: 1%-2%; mortality: 39.7%-66.0%), pericarditis (case fatality rate: ~13%), and accelerated atherosclerosis. Risk profiles differ across ICI agents; CTLA-4 inhibitors, for example, demonstrate more pronounced and dose-dependent cardiotoxicity, and combination therapies are associated with higher risks compared to monotherapy. The pathogenic mechanisms are attributed to loss of immune tolerance, which involves excessive activation of T cells, triggering autoimmune responses; cross-reactive T cells targeting shared cardiac antigens; and cytokine release storms that promote systemic inflammation. Although advances have been made in the diagnosis and management of cardiovascular toxicities associated with ICIs, several challenges persist. These include an incomplete understanding of the underlying mechanisms and a lack of reliable predictive biomarkers. Research should prioritize elucidating the pathogenic pathways, refining combination therapy regimens, identifying novel therapeutic targets, and developing artificial intelligence (AI)-based predictive models. Such efforts are crucial in mitigating toxicity, enhancing patients' quality of life, and improving long-term outcomes.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- School of Heilongjiang, University of Chinese Medicine, Harbin, China.
- Department of Nursing, Hebei General Hospital, Shijiazhuang, China.
- Department of Cardiology, Hebei General Hospital, Shijiazhuang, China.
- School of Heilongjiang, University of Chinese Medicine, Harbin, China. 149772105@qq.com.
- Department of Internal Medicine, Fourth Affiliated Hospital, Heilongjiang University of Chinese Medicine, Harbin, China. doujinjin@hljucm.edu.cn.
Förderung
- 2024 Annual Hospital-Level Talent Special Fund of the Fourth Affiliated Hospital of Heilongjiang University of Chinese Medicine
- Heilongjiang Province "Outstanding Young Teachers Basic Research Support Program" Project
- Scientific Research Project of Heilongjiang University of Chinese Medicine
- Heilongjiang Province “Outstanding Young Teachers Basic Research Support Program” Project
Zitieren
APA
Chen, Z., Zheng, M., Li, Y., Zhang, X., & Dou, J. (2026). Immune Checkpoint Inhibitor–Associated Cardiovascular Toxicity: Mechanisms, Clinical Manifestations, and Clinical Impact. Cardiovascular Toxicology. https://doi.org/10.1007/s12012-026-10131-w
Vancouver
Chen Z, Zheng M, Li Y, Zhang X, Dou J. Immune Checkpoint Inhibitor–Associated Cardiovascular Toxicity: Mechanisms, Clinical Manifestations, and Clinical Impact. Cardiovascular Toxicology. 2026. doi:10.1007/s12012-026-10131-w
BibTeX
@article{Chen2026,
author = {Chen, Zhengyu and Zheng, Meijie and Li, Yuxuan and Zhang, Xiwu and Dou, Jinjin},
title = {Immune Checkpoint Inhibitor–Associated Cardiovascular Toxicity: Mechanisms, Clinical Manifestations, and Clinical Impact},
journal = {Cardiovascular Toxicology},
year = {2026},
doi = {10.1007/s12012-026-10131-w}
}
EUVIMED